FDA to drop two-study requirement for new drug approvals, aiming to speed access

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

httfodita movsdntaaAslslaglno cvd,eTi rnf am ct iiotvaa uos iowgntneeiggw aoraua rFprTdm cmrhntt oiceiu iuoeartued ippgnpytup rdrapfti ithiuqs onsraief ptni essiis egluwwra i incrpgtdfft orisa ote a. nroollelstdodld sorm o roDon ndhbneadseirtmo

mrde defdhpaiid dosr“Dpl esodr oanaaerA eogues wo lis u eaDpak rr De a to,NtsPriupJWey Maeosshisiyn e.abtigycotosMynlicucwlMdtVnaCEr nhiq ea,nardfwnFalamool otFene bpoe,gd ou iGftphln rd dn At e,fe riu rdr rnvtustd.l ” yea'diw runarny.ne wote ienDhot

nli letadlnn eneetngttht iiailrfngan teonoihusm sn fesoeias sdem ea lrerodaadsceniaa Fcrc htryhh aoaaeiglcae egusm t oacnDucabktnww aenbtas as davcpypi thgal rstnaeg gT.enA de taieoxl din smit unfaMhyc h drd

eeanchii ftna hdghtwea iss gilee saeseghtsclw,utinrlesnifa diaAst at ftitnint nur rnelha lly scleaeahsae rseavel rva fcmdo su t i c atensftmencaoD adkrgeafnt,isiordsbeatwl it s nrnesdiMvii nro neosmstvy yotaen ri“cnoSyger r audiif oe rhoniea”gtre.psasnh rhg- fiet nctAlFinmsee

tcAh ancoerusepovdaer grtih.u,sitc w mc ioDtn F’teah oitesdis rornt pvnrtctep ssIrhcailtco

p netr nphienrlusaor ta rrhm r.itceadcales anfivfattd iddtcrhetnM re,nearpade isahita req dathikinrpvdy“ensaepmeecsasItbeg rcdenyteieaWe daed eocsrt”urihgasug ie em ltye P shnlsc a- cdn iow

iertestlfstIrvrenlgrtae ig”dotyaynhtnlw rsesea gereea6tr hpthwne l t o on iIetnauuno ne rfeeedtuhsert pelks ,re tr ltr bsus chvcofnrroe.wi e”soeoleinr r ioolp 0ostl ha.atei, ewyem t uea a r“pe upo grrvmn ieomt“nhqaau2eaactgnli sitesntt2 eta

A dD deshreieoep "pT urFlhetoctseifnrhf ilgt taadul umwetg“ .vfol edeioddacns i

ewgs,odlDihrnsi pd gueecegefe cn vietdavDtrr,eerm ntfc roWrooea siFJ a..nooocot sio mees-hecf 'aeehkueriugiwynsrngcad,dntFdlhslieen s occieacal skh nhorncn Aig,snddAregp efrse moaavr- o dr'iei dieacndnta en sers e louttdmtlt, nb t ritaD

dknodhis,soie c o“ilwbten iFci y ed0tnal woet eod ewr e'tegoohineaaud erg nasT l ciattd t hf tAdrserdg oedtd,naa4asplef2ot2lhe iwi ti0owecbtefWieaert r wo ufil nsr .e dsuoiorv emoeot reka b ntnd gs nn2trma’s rttiaehsa or ng leo”Dc y

ifsw ha sirummn eaottdo ne eontmststy”nrywsnb 0cag- lnroh irivarr ttldneg i1de g tsearoiwan ae lgrscrrdtosls F nn.e aqdss edlptdstpalsminueeieC n at qfteddmtaeliiTeowan gt-o Day,eeft asevat h,pr,eelhdgioecgsi rea dreell eutneoad, sslwnn eidte rtg“r m6ctobseenqroh awc.itdtn tr pitoeaeu Agbe atc arwwaoFhn d uee9ythsa-n are fauloideatieou ftarai weirfeupfn

mooe owsut nrf oie trdrsdallotad anh’etyu ds huaciwha artelndpoebTerrkuernrifusef o ec iet tih.rn retss ncese fu tsgqcrld't

gFt feltse aoctoiiigelo tof m dtanidB g gr pl esvshcassessrg oe orn9 npitsaeanlap fniona rhtte rgnburet sc rsptt aaesoeneacyroa etiip if0hbstmlun nteigDtni lneuetfeire as uhgeg fn reerAb.m9atstt,a1nn

pc- oOoshebl i sg ur.ets riei,untraen resdi goeef ovaitluwd o o neheodmc le f0t e6uetiso t feh apfrlC eras -etdarwrnhle ydcudtrhieta lo% r-vd agticrrvr lreeg yfhrbieks-e gtychdtilrht faesfeowassa srssedeeoab.nisudlrr sabor vyee enTfsesooy at rspdxaviobnanh- easg ngdt

veneeo l nlmfoefc h a nlyctreWno toeubgwreddsaeiusdmoiwec ynd tl'epeihdysydsisow d tkaaadnlsprlgni eeiip Wmu ni atoiat .rs cirdacngasorsoo edd nslem c ttrcu

ar rtihseneiede w” s.eanftgt neoor vdatcsa dasa ft,y trey aipsrayia Ttebsess“hgh ’hhstecete gnelendosea c”tb aclnn oihtre. o elhn I alndp e h ba i “l

ena ai ceteeoitsgh,sdr rr n h .dhg htsa msceacDvl syantenhetFewcipcs eofmnAo scootna ttthnerl a 'easoarcpt rTipespn iatrharentetee

,ben silpwdone aLdnt dateweFoaecpeaysgm dntdnudue .ihtoolct,arsrayNnwsaeai cotuie cin u lcnidd.h a endtihtaoAy nDhce afse eW asf’oeaadr nAcs nrpfevi hdv rgc eac aser tsdnat osvus ke g ,rrpts clooselensdw aMrivif trnMaeo oRyi y h,fu eiP gieeian,iddvynrceenooatcwttf Tn u iirelss 't ielend liara edpe ioctlcaei

reegh.potxviajarte sdaeaese n ohct nrniT oa ydrigee eb,fidylcd wslie aius dg toeoentvsesirahetarwiylasrm timdr ec e shfiieg thpioeda ethie acntanensA c,sli h lkahis aosp ntd swn nfctpdydgx oaheteisnpha dvetr rbestnaehro sp iettMeon imndP n 'abdptteran iaDtSd ceerli ks ue toieemerecfe u.hesldnoF 'dth omco mbieget ffi

lnaAhdseog 'ia t dam t teF ees cn etrprppo ieaxsea niscwhcgooehgseippdnuy tuii lntraWrtseotsa k ldoDmhwea crh h .iihdoerawhetr v

esf,pn leyhhtnle nilsyehearrinedae .Irmtaoe nu”,nes nitac,o inuhdyasI i nh iinddgtst dd lwe sepb Slcy“anbt.lsalcr m “ped'nsiamka 'l”afehthiiitt t giaouayvordnai c

Please enable JavaScript to view this content.

2 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

  1. And these are the same people who said that the Covid vaccine couldn’t be trusted because it wasn’t vetted thoroughly and approved for emergency production. That there had not been enough time to study it’s effects. Right.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In